Goldman Sachs: 'we view DNLI as attractive given the aforementioned dynamics'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $35.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
